Effect of a local anesthetic lozenge in relief of symptoms in burning mouth syndrome

OBJECTIVE: Patients with burning mouth syndrome (BMS) often represent a clinical challenge as available agents for symptomatic treatment are few and often ineffective. The aim was to evaluate the effect of a bupivacaine lozenge on oral mucosal pain, xerostomia and taste alterations in patients with BMS.

METHODS: Eighteen 18 patients (4 men and 14 women) aged 39-71 years with BMS were included in this randomized, double-blinded, placebo-controlled, cross-over trial. Lozenges (containing bupivacaine or placebo) were administrated three times a day for two weeks for two separate treatment periods. Assessment of oral mucosal pain, xerostomia and taste alterations was performed in a patient diary on a visual analogue scale (ranging from 0-100 mm) before and after the lozenge was dissolved.

RESULTS: The bupivacaine lozenge significantly reduced the burning oral pain (p<0.001), increased the sense of taste disturbances (p<0.001), and had no impact on xerostomia, when adjusted for the treatment period.

CONCLUSIONS: Our results indicate that the bupivacaine lozenge offers a novel therapeutic modality to patients with BMS, although without alleviating effect on the associated symptoms, taste alterations and xerostomia. This article is protected by copyright. All rights reserved.